Adage Capital Partners
ASND icon

Adage Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Adage Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-459,606
Closed -$79.3M – 886
2025
Q2 		$79.3M Buy
459,606
+132,201
+40% +$21.5M 0.13% 152
2025
Q1 		$51M Buy
+327,405
New +$46.8M 0.09% 222
2024
Q4 		– Sell
-486,957
Closed -$72.7M – 878
2024
Q3 		$72.7M Sell
486,957
-333,555
-41% -$45M 0.13% 165
2024
Q2 		$112M Buy
820,512
+611,000
+292% +$83.1M 0.21% 94
2024
Q1 		$31.7M Buy
209,512
+65,512
+45% +$9.35M 0.06% 339
2023
Q4 		$18.1M Sell
144,000
-382,371
-73% -$38.1M 0.04% 450
2023
Q3 		$49.3M Sell
526,371
-162,629
-24% -$15.2M 0.11% 200
2023
Q2 		$61.5M Buy
689,000
+189,000
+38% +$16.4M 0.13% 169
2023
Q1 		$53.6M Sell
500,000
-140,000
-22% -$16M 0.12% 201
2022
Q4 		$78.2M Buy
640,000
+410,000
+178% +$47.6M 0.19% 131
2022
Q3 		$23.8M Buy
230,000
+65,000
+39% +$6.16M 0.06% 359
2022
Q2 		$15.3M Sell
165,000
-7,000
-4% -$660K 0.04% 536
2022
Q1 		$20.2M Buy
172,000
+122,000
+244% +$14.1M 0.04% 447
2021
Q4 		$6.73M Buy
+50,000
New +$7.44M 0.01% 784
2020
Q3 		– Sell
-30,000
Closed -$4.44M – 756
2020
Q2 		$4.44M Sell
30,000
-10,000
-25% -$1.37M 0.01% 637
2020
Q1 		$4.5M Hold
40,000
– – 0.01% 584
2019
Q4 		$5.57M Sell
40,000
-160,000
-80% -$17.8M 0.01% 600
2019
Q3 		$19.3M Sell
200,000
-50,000
-20% -$5.58M 0.05% 376
2019
Q2 		$28.8M Buy
250,000
+25,000
+11% +$2.99M 0.07% 300
2019
Q1 		$26.5M Sell
225,000
-100,000
-31% -$8.76M 0.07% 318
2018
Q4 		$20.4M Buy
325,000
+75,000
+30% +$4.71M 0.06% 321
2018
Q3 		$17.7M Buy
250,000
+25,000
+11% +$1.72M 0.04% 428
2018
Q2 		$15M Sell
225,000
-350,000
-61% -$23M 0.03% 474
2018
Q1 		$37.6M Buy
575,000
+556,000
+2,926% +$31.2M 0.09% 274
2017
Q4 		$761K Buy
+19,000
New +$691K ﹤0.01% 684

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners's ASND Position: Q3 2025 in Review

Adage Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 459,606 shares — an estimated $79.3M sold.

Adage Capital Partners first reported a position in ASND in Q4 2017 and held it in 25 quarters. The position peaked at $112M in Q2 2024. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

  • Adage Capital Partners reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 459,606 Ascendis Pharma A/S shares in Q3 2025, an estimated $79.3M.
  • Adage Capital Partners first reported a position in Ascendis Pharma A/S in Q4 2017 and held it in 25 quarters.
  • Adage Capital Partners's Ascendis Pharma A/S position peaked at $112M in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.